Hot Sale Wholesale Tirz/Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides Betty
28 Inquiries
2460055-10-9
ep
99.9%
HongKong
19-2 Vial
2026-11-05
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceFOXO4-DRI (Retro-Inverso) is a synthetic, slightly modified version of the standard FOXO4 protein. The modification prolongs half-life of the protein and allows it to interfere with normal FOXO4 function. FOXO4-DRI has been shown in research to prevent normal FOXO4 binding to p53, thereby allowing for elimination of senescent cells, improved organ function, and younger tissue “biological age.” FOXO4-DRI impacts insulin signaling, cell cycle regulation, and oxidative stress signaling pathways. FOXO4-DRI is a cell penetrating peptide shown to selectively induce apoptosis of senescent cells thereby reversing effects of aging in animal studies.Basic Info
-
Product Name:
FOXO4-DRI
Other Name:FOXO4-DRI;FOXO4 /FOXO4-DRI;FOX04-DRI (D-Retro-Inverso);Fox4-dri
CAS No.:2460055-10-9
Molecular Weight:0
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History28 Inquiries
Country Product Purchase Quantity Date Posted
United States
FOXO4-DRI
1 G Dec 3, 2023
Germany
foxo4-dri
1 G Aug 23, 2026
United States
Fox04-dri
1 G May 20, 2026
United States
hot-sale-high-purity-raw-powder-fox04-dri-nad-ghk-cu-mot
2 PCS Dec 19, 2025
United States
foxo4 dri
10 MT Dec 13, 2025
United States
Fox04
10 MG Oct 30, 2024
Norway
FOXO4-DRI
200 MG Sep 3, 2026
United Kingdom
High purity foxo4
1 G May 31, 2026
United Kingdom
Foxo4-Dri
10 MG May 5, 2026
United States
Fox04-dri
100 MG Apr 28, 2026
Cyprus
Foxo4 dri
10 MT Apr 4, 2026
Cyprus
FOXO4-DRI
1 KG Feb 2, 2026
United States
FOX04-DRI
10 PCS Jan 12, 2026
United States
FOX04
10 PCS Jan 12, 2026
United States
Foxo4 Dri
40 MG Sep 15, 2025
United States
Fox04 dri
10 MT Jun 21, 2026
United States
FOX04-DRI powder
10 MT May 29, 2026
United States
fox04
1 G Apr 29, 2026
United States
FOXO4-DRI
1 KG Mar 23, 2026
United States
Foxo4-Dri
2 Nov 24, 2025 Post an enquiry for this product